American Association for Cancer Research
15417786mcr181370-sup-214463_3_supp_6035773_q4dwz9.pdf (1.66 MB)

Figure S1 from c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein

Download (1.66 MB)
journal contribution
posted on 2023-04-03, 17:01 authored by Severa Bunda, Pardeep Heir, Annie Si Cong Li, Yasin Mamatjan, Gelareh Zadeh, Kenneth Aldape

Figure S1 shows that Dasatinib a selective Src kinase inhibitor only affects the viability of GBM derived cells with elevated Src kinase activity.


Canada Cancer Society Research Institute Innovation



Capicua (CIC) is a transcriptional repressor that counteracts activation of genes in response to receptor tyrosine kinase (RTK)/Ras/ERK signaling. Following activation of RTK, ERK enters the nucleus and serine-phosphorylates CIC, releasing it from its targets to permit gene expression. We recently showed that ERK triggers ubiquitin-mediated degradation of CIC in glioblastoma (GBM). In this study, we examined whether another important downstream effector of RTK/EGFR, the non-RTK c-Src, affects CIC repressor function in GBM. We found that c-Src binds and tyrosine-phosphorylates CIC on residue 1455 to promote nuclear export of CIC. On the other hand, CIC-mutant allele (CIC-Y1455F), that escapes c-Src–mediated tyrosine phosphorylation, remains localized to the nucleus and retains strong repressor function against CIC targets, the oncogenic transcription factors ETV1 and ETV5. Furthermore, we show that the orally available Src family kinase inhibitor, dasatinib, which prevents EGF-mediated tyrosine phosphorylation of CIC and attenuates elevated ETV1 and ETV5 levels, reduces viability of GBM cells and glioma stem cells (GSC), but not of their control cells with undetectable c-Src activity. In fact, GBM cells and GSC expressing the tyrosine-defective CIC mutant (Y1455F) lose sensitivity to dasatinib, further endorsing the effect of dasatinib on Src-mediated tyrosine phosphorylation of CIC. These findings elucidate important mechanisms of CIC regulation and provide the rationale to target c-Src alongside ERK pathway inhibitors as a way to fully restore CIC tumor suppressor function in neoplasms such as GBM. c-Src tyrosine-phosphorylates CIC exports to cytoplasm and inactivates its repressor function in GBM.

Usage metrics

    Molecular Cancer Research



    Ref. manager